Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agoni...
Ahmad Hassan, Qurrat Ul Ain Farooq, Fnu Parwesh et al.· F1000Research· 0 citations
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States and frequently associated with advanced stages complicated by respiratory failure (RF), a major terminal event that has been epidemiologically associated with significantly higher mortality risk among COPD pa...
Affaf Mahmood, Farah Latif, Abdul Haseeb Hasan· Annals of Medicine and Surge...· 0 citations
Obesity is a chronic, multifactorial disease characterized by excessive adiposity and associated with an increased risk of cardiovascular disease, type 2 diabetes, and reduced quality of life. Despite the widespread adoption of lifestyle interventions, long-term weight maintenance remains challenging, highlighting the...
Fnu Zainab, Abdul Haseeb Hasan· Annals of Medicine and Surge...· 0 citations
Background Left atrial appendage occlusion (LAAO) offers a mechanical alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation patients. However, the optimal anesthetic strategy—general anesthesia (GA) versus conscious sedation (CS)—during LAAO remains unclear. Methods A systematic sear...
Abubakar Nazir, Ahmad Hassan, Maaz Amir et al.· F1000Research· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed non-alcoholic fatty liver disease (NAFLD), affects a substantial proportion of the global adult population and is a leading cause of chronic liver disease. Its progression reflects interactions among metabolic dysfunction, genetic suscept...
E. Abady, Hazem AbuEl-Enien, Panos I. Tamvakologos et al.· Discover medicine· 0 citations
Mitapivat represents a significant advance in thalassemia management by targeting erythrocyte metabolism and providing the first FDA‐approved oral treatment for anemia in adults with α or β thalassemia.
Fnu Zainab, Abdul Haseeb Hasan, Muhammad Hafi Abid et al.· Health Science Reports· 0 citations
Findings support individualized use of rivaroxaban-based therapy in carefully selected patients, balancing ischemic and limb-protective benefits against bleeding risk, and support individualized use of rivaroxaban-based therapy in carefully selected patients.
M. Shahzaib, Muhammad Roshaan, M. K. Buhadur Ali et al.· Annals of Vascular Surgery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
